Published: Wed, March 14, 2018
Medical | By Johnnie Horton

Sarepta Therapeutics (SRPT) PT Set at $81.00 by Credit Suisse Group

After a recent check, the 14-day RSIfor Revive Therapeutics Ltd (RVV.V) is now at 48.91, the 7-day stands at 57.54, and the 3-day is sitting at 68.27.

Today, HC Wainwright raised its price target on Sarepta Therapeutics (NASDAQ:SRPT) to per share. Therefore 81% are positive. The current share price indicates that stock is -42.24% away from its one year high and is moving 30.31% ahead of its 52-week low. After the latest check-in, company stock is 0.84% off of the 50 day high and 59.63% away from the 50 day low price.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $75.77. Needham maintained it with "Buy" rating and $75.0 target in Thursday, October 26 report. It improved, as 24 investors sold Sarepta Therapeutics, Inc. shares while 27 reduced holdings. (NASDAQ:SRPT). Schwab Charles Investment Mngmt owns 268,553 shares or 0.01% of their USA portfolio. As per Tuesday, January 19, the company rating was downgraded by RBC Capital Markets. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Friday, December 16. RBC Capital Markets maintained the shares of SRPT in report on Friday, October 28 with "Outperform" rating. This based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell. The rating was maintained by Roth Capital on Thursday, September 3 with "Buy". Independent Research downgraded the stock to "Hold" rating in Wednesday, December 7 report. The firm has "Neutral" rating by Buckingham Research given on Wednesday, August 2. Emerald Mutual Fund Advisers Tru has 1.36% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has "Overweight" rating given on Tuesday, March 6 by Morgan Stanley. The firm has "Neutral" rating by UBS given on Thursday, October 19. The stock decreased 0.94% or $1.02 during the last trading session, reaching $106.94. About 70,952 shares traded. One Liberty Properties, Inc. It has underperformed by 15.45% the S&P500. Cornerstone Management Holdings Limited Liability Corporation owns 2,600 shares. 137.76 million shares or 2.31% less from 141.01 million shares in 2017Q2 were reported. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by ($0.05). The New York-based Salzhauer Michael has invested 0.35% in the stock. The Osterweis Capital Management Inc holds 98,925 shares with $4.49M value, down from 112,900 last quarter. The TSXV listed company saw a recent bid of $0.34 and 2210000 shares have traded hands in the session. Pura Vida Investments Llc acquired 20,000 shares as Sarepta Therapeutics Inc (SRPT)'s stock rose 22.49%.

Pura Vida Investments Llc increased Sarepta Therapeutics Inc (SRPT) stake by 66.67% reported in 2017Q3 SEC filing. It has outperformed by 80.12% the S&P500.

The Altria Group Inc (MO) Shares Sold by Cadence Capital Management LLC
Johnson sold 14,953 shares of the company's stock in a transaction that occurred on Thursday, February 8th. Interocean Limited Liability Company has invested 0.08% in Altria Group, Inc . (NYSE:MO) or 12,264 shares.

Since October 3, 2017, it had 0 buys, and 1 sale for $575,000 activity. It increased, as 24 investors sold SRPT shares while 27 reduced holdings.

If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. The S&P 500 index fell 3.55 points, or 0.1%, to 2,783.02, with the industrials sector shedding more than 1.2%. Sigma Planning has 21,350 shares for 0.08% of their portfolio. Columbus Circle Investors stated it has 121,758 shares or 0.09% of all its holdings. Ls Advsr Ltd Liability Corporation owns 1,807 shares for 0% of their portfolio. C WorldWide Group Holding A S raised its holdings in Sarepta Therapeutics by 0.8% during the 3rd quarter. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since March 12, 2017 and is uptrending. (NASDAQ:SRPT) for 8,300 shares. (NASDAQ:SRPT). California State Teachers Retirement System accumulated 94,770 shares or 0.01% of the stock. Parametric Portfolio Associate Ltd Liability Co has 0% invested in Meridian Bioscience, Inc. The institutional investor held 150,000 shares of the health care company at the end of 2017Q3, valued at $6.80 million, down from 383,047 at the end of the previous reported quarter. The stock of Meridian Bioscience, Inc.

Revive Therapeutics Ltd (RVV.V) has a 14-day ATR of 0.03. Driehaus Mngmt Limited Company holds 0.13% of its portfolio in Sarepta Therapeutics, Inc. Cubist Systematic Strategies Lc holds 1,786 shares or 0% of its portfolio. Sarepta Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $68.73.

Sarepta Therapeutics, a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Like this: